Sotagliflozin：禮來！FDA批准糖尿病藥SGLT12雙重抑制劑治療心衰竭
禮來！FDA批准糖尿病藥SGLT12雙重抑制劑治療心衰竭
胰島素是目前治療第一型糖尿病的主要藥物
https://www.taiwan-pharma.org.
新型口服藥物sotagliflozin是一種SGLT1與SGLT2 （sodium-glucose cotransporters 1 and 2）抑制劑。抑制SGLT1會減少糖份在近端小腸的吸收，能夠減少與延緩餐後高血糖發生；抑制 ...
賽諾菲口服糖尿病藥物sotagliflozin上市申請被美國FDA拒絕
https://ibmi.taiwan-healthcare
3月23日，賽諾菲與合作夥伴Lexicon宣佈其SGLT1/2雙抑制劑sotagliflozin（商品名Zynquista）用於治療成人一型糖尿病的上市申請被美國FDA拒絕，但具體原因 ...
Sotagliflozin in Patients with Diabetes and Recent ...
https://www.nejm.org
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes ...
Sotagliflozin
https://pubchem.ncbi.nlm.nih.g
It has a role as a sodium-glucose transport protein subtype 2 inhibitor, a hypoglycemic agent, an antihypertensive agent, a cardioprotective agent and a sodium- ...
Sotagliflozin
https://en.wikipedia.org
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure.
Sotagliflozin in Patients with Diabetes and Chronic Kidney ...
https://www.nejm.org
Sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart ...
Inpefa (sotagliflozin) dosing, indications
https://reference.medscape.com
Indicated to reduce risk of cardiovascular (CV) death, hospitalization for heart failure (HF), and urgent visits for HF in adults with HF or type 2 diabetes.
Sotagliflozin
https://medlineplus.gov
Sotagliflozin is used to reduce the risk of a stroke, heart attack, or death or hospitalization for heart failure or urgent visits for heart ...
Metabolic
https://www.ncbi.nlm.nih.gov
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor approved in the European Union for use as an adjunct to insulin therapy in patients with type 1 diabetes (T1D) ...